Repligen Corp (RGEN) Stock Price & Analysis
Repligen Corp (RGEN) rose 3.83% to USD 130.13 as of June 10, 2026 at 03:13 UTC, according to Nexqual real-time market data.
RGEN last closed at USD 125.33; the session ranged USD 127.42–132.25 on volume of 1,466,588 shares. Market capitalization is $7.34B, with a 52-week range of USD 100.99–175.77 (NMS). Source: Nexqual, June 10, 2026 at 03:13 UTC.
Key Statistics (as of June 10, 2026 at 03:13 UTC)
| Price | USD 130.13 |
|---|---|
| Change | ▲ 3.83% (up) |
| Previous Close | USD 125.33 |
| Open | USD 127.49 |
| Day Range | USD 127.42 – 132.25 |
| 52-Week Range | USD 100.99 – 175.77 |
| Volume | 1,466,588 shares |
| Market Cap | $7.34B |
| Exchange | NMS |
Technical Analysis (RGEN)
Nexqual's technical model rates RGEN "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:13 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.89 (neutral) |
| vs SMA50 | Above (USD 119.33) |
| MACD | 2.37 (positive) |
Analyst Ratings (RGEN)
Wall Street analysts rate RGEN "Buy" based on 19 analysts, with a mean price target of USD 176.11 (range USD 142–220), per Nexqual as of June 10, 2026 at 03:13 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 19 |
| Mean Target | USD 176.11 |
| High Target | USD 220 |
| Low Target | USD 142 |
| Buy / Hold / Sell | 18 / 4 / 0 |
Earnings (RGEN)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.45 |
| Revenue Estimate | $201.42M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.48 vs est 0.39 ▲ beat |
| 2025-12-31 | USD 0.49 vs est 0.44 ▲ beat |
| 2025-09-30 | USD 0.46 vs est 0.41 ▲ beat |
| 2025-06-30 | USD 0.37 vs est 0.39 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financials & Fundamentals (RGEN)
| Total Revenue | $763.34M |
|---|---|
| Revenue Growth (YoY) | +14.80% |
| Gross Margin | +53.14% |
| Operating Margin | +8.90% |
| Profit Margin | +6.73% |
| ROE | +2.51% |
| Debt / Equity | 32.66 |
| Current Ratio | 9.2 |
| Total Cash | $784.53M |
| Total Debt | $687.62M |
| Free Cash Flow | $68.72M |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financial Health Score (RGEN)
Nexqual rates Repligen Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 03:13 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 53%, operating 9% |
| Balance Sheet | Strong — $785M cash vs $688M debt, net cash position |
| Cash Flow | Solid — FCF $69M, 9% margin |
| Efficiency | Weak — ROE 3%, ROA 1.2% |
Ownership (RGEN)
| Insider Ownership | +5.25% |
|---|---|
| Institutional Ownership | +119.67% |
| Shares Outstanding | 56.41M |
| Float | 53.36M |
| Short % of Float | +10.60% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Leadership (RGEN)
Repligen Corp is led by Olivier Loeillot (age 55), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:13 UTC.
| President, CEO & Director | Olivier Loeillot (age 55) |
|---|---|
| CFO & Chief Compliance Officer | Jason K. Garland (age 51) |
| Chief Operating Officer | James R. Bylund (age 61) |
| Senior Vice President of Research & Development | Ralf Kuriyel (age 67) |
| Senior VP & Chief Product Officer | Brian Douglass (age 50) |
Major Backers & Investors (RGEN)
Notable institutional backers of Repligen Corp include Price (T.Rowe) Associates Inc, FMR, LLC, United Capital Financial Advisors, LLC, according to Nexqual as of June 10, 2026 at 03:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 9.72% |
| FMR, LLC | 5.12% |
| United Capital Financial Advisors, LLC | 4.92% |
| T. Rowe Price | 3.46% |
| Maverick Capital Ltd. | 2.69% |
| Massachusetts Financial Services Co. | 2.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.05% |
| Vanguard Group | 14.78% |
| State Street | 3.15% |
| BNY Mellon | 2.71% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
From Repligen Corp's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
- The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
- It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NBIX | Neurocrine Biosciences, Inc. | USD 165.24 | ▲ 0.83% |
| QDEL | QuidelOrtho Corporation | USD 13.94 | ▼ 2.72% |
| NVCR | NovoCure Limited | USD 17.24 | ▲ 0.47% |
| MASI | Masimo Corporation | USD 179.95 | ▲ 0.63% |
| PODD | Insulet Corporation | USD 159.61 | ▲ 4.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:13 UTC. This page is informational and not investment advice.